These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7075116)

  • 1. Effects of high-dose cytarabine.
    Hande KR; Stein RS; McDonough DA; Greco FA; Wolff SN
    Clin Pharmacol Ther; 1982 May; 31(5):669-74. PubMed ID: 7075116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
    Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
    J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
    Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
    J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
    Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
    Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
    Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
    Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
    Sinkule JA; Evans WE
    J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system.
    Ho DH; Brown NS; Benvenuto J; McCredie KB; Buckels D; Freireich EJ
    Clin Pharmacol Ther; 1977 Sep; 22(3):371-4. PubMed ID: 268246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC; Karp JE; Burke PJ
    Cancer Treat Rep; 1986 Sep; 70(9):1059-65. PubMed ID: 3461882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
    Liliemark JO; Gahrton G; Paul CY; Peterson CO
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clincal pharmacology of O2,2'-cyclocytidine.
    Rodriguez DH; Loo TL; Bodey GP; Freireich EJ
    Clin Pharmacol Ther; 1975 Jan; 17(1):66-72. PubMed ID: 1173058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.